Skip to content

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Exploratory Neuroimaging Study to Evaluate the Effect on Brain Activity of SPN-810 for Impulsive Aggression (IA) in Patients With Attention-Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03638466
Enrollment
7
Registered
2018-08-20
Start date
2019-05-30
Completion date
2019-11-07
Last updated
2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression

Brief summary

The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA). This was achieved using functional magnetic resonance imaging (fMRI) in conjunction with the point subtraction aggression paradigm (PSAP) Task, a behavioral aggression paradigm in which subjects are provoked by having money indirectly taken from them by a fictitious opponent, simulating an aggression response.

Detailed description

Approximately 30 subjects aged 8-12 diagnosed with ADHD and associated feature of IA were recruited in this study. The PSAP is a behavioral aggression test used to evaluate behavioral response related to impulsive aggression. The task was combined with functional MRI to evaluate the change in brain activity measured as BOLD signal (blood oxygenation level-dependent) from baseline to the end of the treatment with SPN-810. The level of neurotransmitters Glutamate and GABA were also measured using magnetic resonance spectroscopy (MRS). Additionally, the improvement and severity in impulsive aggression behaviors were assessed using validated scales.

Interventions

DIAGNOSTIC_TESTFunctional Magnetic Resonance Imaging (fMRI)

Neural brain activity measured by fMRI

Glutamate and GABA levels measured by MRS

BEHAVIORALPoint Subtraction Aggression Paradigm (PSAP) Task

Aggression score measured by the PSAP task

Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score

DRUGPlacebo

Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score

Sponsors

Supernus Pharmaceuticals, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study

Eligibility

Sex/Gender
ALL
Age
8 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Otherwise healthy male or female subjects, aged 8-12 years, inclusive, at the time of screening with primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized US Food and Drug Administration (FDA)-approved ADHD medication. * Impulsive aggression (IA) confirmed at screening using the R-MOAS and the Vitiello Aggression Scale.

Exclusion criteria

* Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette's disorder, fetal alcohol syndrome, or psychosis not otherwise specified. * Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder. * Known or suspected IQ \<70, pregnancy, substance or alcohol abuse. * Known history of implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, orthodontic braces, or implanted medication port. Visual and hearing (≥25 dB) impairment. * Pre-existing medical or psychological conditions that preclude being in the MRI scanner (e.g., claustrophobia, morbid obesity, or marked anxiety about the procedure).

Design outcomes

Primary

MeasureTime frameDescription
Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskBaseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.
Effect of SPN-810 on the Aggressions ScoreBaseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the aggression action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.
Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskBaseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.

Secondary

MeasureTime frameDescription
Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.

Other

MeasureTime frameDescription
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) ScaleFrom Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) ScoreVisit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) ScaleVisit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.

Countries

United States

Participant flow

Recruitment details

A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study

Participants by arm

ArmCount
Placebo
Subjects treated with Placebo
4
High Dose SPN-810 (36 mg)
Subjects treated with SPN-810
3
Total7

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyEarly Termination01

Baseline characteristics

CharacteristicHigh Dose SPN-810 (36 mg)PlaceboTotal
Age, Categorical
<=18 years
3 Participants4 Participants7 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous11.3 years
STANDARD_DEVIATION 1.15
9.5 years
STANDARD_DEVIATION 1.29
10.3 years
STANDARD_DEVIATION 1.5
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants2 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants2 Participants3 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Impulsive Aggression Measured by Clinical Global Impression - Severity Scale (CGI-S) Score5.0 units on a scale
STANDARD_DEVIATION 1.41
5.8 units on a scale
STANDARD_DEVIATION 0.96
5.5 units on a scale
STANDARD_DEVIATION 1.05
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants3 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants1 Participants
Race (NIH/OMB)
White
1 Participants2 Participants3 Participants
Region of Enrollment
United States
3 participants4 participants7 participants
Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score57.0 units on a scale
STANDARD_DEVIATION 6
102.5 units on a scale
STANDARD_DEVIATION 32.3
83.0 units on a scale
STANDARD_DEVIATION 33.54
Sex: Female, Male
Female
2 Participants0 Participants2 Participants
Sex: Female, Male
Male
1 Participants4 Participants5 Participants
Vitiello Aggression Total Score-3.7 units on a scale
STANDARD_DEVIATION 1.53
-3.5 units on a scale
STANDARD_DEVIATION 1.29
-3.6 units on a scale
STANDARD_DEVIATION 1.27

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 3
other
Total, other adverse events
2 / 41 / 3
serious
Total, serious adverse events
0 / 40 / 3

Outcome results

Primary

Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task

The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.

Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.5145 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskSuperior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskInferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5353 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.5133 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.5173 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskMedial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.5128 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.5258 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.50 Voxels
SPN-810 (36 mg) > PlaceboAggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5110 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.5110 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskInferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskLeft Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskMedial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.50 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskSuperior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.5329 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.5175 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.5164 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.5140 Voxels
Placebo > SPN-810 (36 mg)Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP TaskRight Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.5145 Voxels
Primary

Effect of SPN-810 on the Aggressions Score

The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the aggression action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.

Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)Dispersion
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on the Aggressions ScoreBaseline/Visit 28.43 score on a scaleStandard Deviation 9.22
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on the Aggressions ScoreVisit 59.26 score on a scaleStandard Deviation 5.5
Placebo > SPN-810 (36 mg)Effect of SPN-810 on the Aggressions ScoreBaseline/Visit 210.23 score on a scaleStandard Deviation 6.21
Placebo > SPN-810 (36 mg)Effect of SPN-810 on the Aggressions ScoreVisit 54.02 score on a scaleStandard Deviation 2.6
Primary

Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task

BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.

Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)
SPN-810 (36 mg) > PlaceboProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskLeft Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.5137 Voxels
SPN-810 (36 mg) > PlaceboProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskLeft Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.50 Voxels
SPN-810 (36 mg) > PlaceboProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskMedial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.50 Voxels
SPN-810 (36 mg) > PlaceboProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskRight Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.50 Voxels
SPN-810 (36 mg) > PlaceboProvocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskRight Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.5318 Voxels
Placebo > SPN-810 (36 mg)Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskRight Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.5109 Voxels
Placebo > SPN-810 (36 mg)Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskRight Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.50 Voxels
Placebo > SPN-810 (36 mg)Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskLeft Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.50 Voxels
Placebo > SPN-810 (36 mg)Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskMedial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.5123 Voxels
Placebo > SPN-810 (36 mg)Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP TaskLeft Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.5122 Voxels
Secondary

Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)

GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.

Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans

ArmMeasureGroupValue (MEAN)Dispersion
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)GABA (mM)0.79 mMStandard Deviation 0.26
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)Glutamate (mM)0.78 mMStandard Deviation 2.44
Placebo > SPN-810 (36 mg)Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)GABA (mM)0.75 mMStandard Deviation 0.67
Placebo > SPN-810 (36 mg)Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)Glutamate (mM)0.23 mMStandard Deviation 1.91
Other Pre-specified

Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale

The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.

Time frame: Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)Dispersion
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) ScaleVisit 42.3 score on a scaleStandard Deviation 1.26
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) ScaleVisit 62.3 score on a scaleStandard Deviation 1.26
Placebo > SPN-810 (36 mg)Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) ScaleVisit 41.5 score on a scaleStandard Deviation 0.71
Placebo > SPN-810 (36 mg)Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) ScaleVisit 61.0 score on a scaleStandard Deviation 0
Other Pre-specified

Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale

The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).

Time frame: From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)Dispersion
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) ScaleVisit 4-1.25 score on a scaleStandard Deviation 1.5
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) ScaleVisit 6-2.25 score on a scaleStandard Deviation 1.5
Placebo > SPN-810 (36 mg)Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) ScaleVisit 4-1.5 score on a scaleStandard Deviation 2.12
Placebo > SPN-810 (36 mg)Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) ScaleVisit 6-1.5 score on a scaleStandard Deviation 2.12
Other Pre-specified

Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score

R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.

Time frame: Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).

Population: Completed population included all subjects randomized, who had a Baseline imaging scan (including the anatomical scan) and post-treatment imaging scans.

ArmMeasureGroupValue (MEAN)Dispersion
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) ScoreVisit 4-52.0 score on a scaleStandard Deviation 30.23
SPN-810 (36 mg) > PlaceboEffect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) ScoreVisit 6-61.0 score on a scaleStandard Deviation 18.81
Placebo > SPN-810 (36 mg)Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) ScoreVisit 4-43.0 score on a scaleStandard Deviation 2.83
Placebo > SPN-810 (36 mg)Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) ScoreVisit 6-39.5 score on a scaleStandard Deviation 24.75

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026